2021
Repeated infusion of mesenchymal stem cells maintain the condition to inhibit deteriorated motor function, leading to an extended lifespan in the SOD1G93A rat model of amyotrophic lateral sclerosis
Magota H, Sasaki M, Kataoka-Sasaki Y, Oka S, Ukai R, Kiyose R, Onodera R, Kocsis JD, Honmou O. Repeated infusion of mesenchymal stem cells maintain the condition to inhibit deteriorated motor function, leading to an extended lifespan in the SOD1G93A rat model of amyotrophic lateral sclerosis. Molecular Brain 2021, 14: 76. PMID: 33962678, PMCID: PMC8103621, DOI: 10.1186/s13041-021-00787-6.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisAdministration of MSCsSingle infusionMesenchymal stem cellsMotor functionGait abilityDisease progressionMotor neuronsRat modelLateral sclerosisBlood-spinal cord barrierSOD1G93A rat modelSpinal cord degenerateVehicle infusion groupHind limb functionALS rat modelStem cellsLimb functionVehicle infusionFatal disorderSurvival periodTherapeutic effectLocomotor activityInfusionProgressive deterioration
2017
Mesenchymal Stem Cells
Sasaki M, Honmou O. Mesenchymal Stem Cells. 2017, 147-156. DOI: 10.1007/978-4-431-56059-3_12.Peer-Reviewed Original ResearchIntravenous infusionMesenchymal stem cellsAdult human bone marrowHuman bone marrowAnimal modelsBone marrowInfused mesenchymal stem cellsHuman stroke patientsSpinal cord injuryInitial clinical studiesInitial human studiesStem cellsAxonal sproutingCerebral strokeStroke patientsCord injuryFunctional improvementClinical studiesTherapeutic effectStroke modelHuman studiesInfusionStrokeMarrowHuman mesenchymal stem cells
2016
Synergic Effects of Rehabilitation and Intravenous Infusion of Mesenchymal Stem Cells After Stroke in Rats
Sasaki Y, Sasaki M, Kataoka-Sasaki Y, Nakazaki M, Nagahama H, Suzuki J, Tateyama D, Oka S, Namioka T, Namioka A, Onodera R, Mikami T, Wanibuchi M, Kakizawa M, Ishiai S, Kocsis JD, Honmou O. Synergic Effects of Rehabilitation and Intravenous Infusion of Mesenchymal Stem Cells After Stroke in Rats. Physical Therapy 2016, 96: 1791-1798. PMID: 27174259, DOI: 10.2522/ptj.20150504.Peer-Reviewed Original ResearchConceptsMiddle cerebral artery occlusionIntravenous infusionDaily rehabilitationMesenchymal stem cellsMSC infusionFunctional outcomePermanent middle cerebral artery occlusionLimb placement testCerebral artery occlusionRat stroke modelRat MCAO modelIntraluminal vascular occlusionMagnetic resonance imagingStem cellsAdult bone marrowArtery occlusionCerebral ischemiaMCAO modelVascular occlusionFunctional improvementLesion volumeTherapy groupTherapeutic effectStroke modelGroup 2
2015
Corrigendum to “Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats” [Neurosci. Lett. 584 (2015) 276–281]
Suzuki S, Kawamata J, Iwahara N, Matsumura A, Hisahara S, Matsushita T, Sasaki M, Honmou O, Shimohama S. Corrigendum to “Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats” [Neurosci. Lett. 584 (2015) 276–281]. Neuroscience Letters 2015, 587: 5. DOI: 10.1016/j.neulet.2014.12.023.Peer-Reviewed Original Research
2014
Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats
Suzuki S, Kawamata J, Iwahara N, Matsumura A, Hisahara S, Matsushita T, Sasaki M, Honmou O, Shimohama S. Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats. Neuroscience Letters 2014, 584: 276-281. PMID: 25449872, DOI: 10.1016/j.neulet.2014.10.039.Peer-Reviewed Original ResearchConceptsHuman bone marrow-derived mesenchymal stem cellsTherapeutic effectParkinson's diseaseCalcium binding adaptor molecule 1Mesenchymal stem cell administrationSubstantia nigra pars compactaHemi-parkinsonian rat modelParkinsonian model ratsTH-positive neuronsAdaptor molecule 1Anti-inflammatory factorsStem cell administrationNovel therapeutic optionsSham-operated ratsBone marrow-derived mesenchymal stem cellsMarrow-derived mesenchymal stem cellsGlial activationPars compactaCell administrationTherapeutic optionsDopaminergic neuronsModel ratsDopaminergic neurodegenerationNovel therapiesRat model
2012
Mesenchymal stem cells: therapeutic outlook for stroke
Honmou O, Onodera R, Sasaki M, Waxman SG, Kocsis JD. Mesenchymal stem cells: therapeutic outlook for stroke. Trends In Molecular Medicine 2012, 18: 292-297. PMID: 22459358, DOI: 10.1016/j.molmed.2012.02.003.Peer-Reviewed Original ResearchConceptsMarrow-derived mesenchymal stem cellsTransplanted MSCsSpinal cord injuryInitial clinical studiesInitial human studiesBone marrow-derived mesenchymal stem cellsAdult bone marrow-derived mesenchymal stem cellsAdult human bone marrowAxonal sproutingCerebral ischemiaClinical outcomesNeuroprotective effectsCord injuryHuman bone marrowClinical studiesTherapeutic effectStroke modelAnimal modelsHuman studiesBone marrowMesenchymal stem cellsIntravenous deliveryTherapeutic outlookMSC deliveryStroke